Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models
- 21 April 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 117 (16) , 4358-4366
Abstract
Type 1 VWD is the mild to moderate reduction of VWF levels. This study examined the mechanisms underlying 2 common type 1 VWD mutations, the severe R1205H and more moderate Y1584C. In vitro biosynthesis was reduced for both mutations in human and mouse VWF, with the effect being more severe in R1205H. VWF knockout mice received hydrodynamic injections of mouse Vwf cDNA. Lower VWF antigen levels were demonstrated in both homozygous and heterozygous forms for both type 1 mutations from days 14-42. Recombinant protein infusions and hydrodynamic-expressed VWF propeptide to antigen ratios demonstrate that R1205H mouse VWF has an increased clearance rate, while Y1584C is normal. Recombinant ADAMTS13 digestions of Y1584C demonstrated enhanced cleavage of both human and mouse VWF115 substrates. Hydrodynamic-expressed VWF shows a loss of high molecular weight multimers for Y1584C compared with wild-type and R1205H. At normal physiologic levels of VWF, Y1584C showed reduced thrombus formation in a ferric chloride injury model while R1205H demonstrated similar thrombogenic activity to wild-type VWF. This study has elucidated several novel mechanisms for these mutations and highlights that the type 1 VWD phenotype can be recapitulated in the VWF knockout hydrodynamic injection model.Keywords
This publication has 38 references indexed in Scilit:
- The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formationBlood, 2009
- ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factorBritish Journal of Haematology, 2008
- Altered thrombus formation in von Willebrand factor–deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIaBlood, 2008
- Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD)Blood, 2008
- The effect of exercise on von Willebrand factor and ADAMTS‐13 in individuals with type 1 and type 2B von Willebrand diseaseJournal of Thrombosis and Haemostasis, 2007
- The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort studyBlood, 2007
- The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort studyBlood, 2006
- Novel monoclonal antibody‐based enzyme immunoassay for determining plasma levels of ADAMTS13 activityTransfusion, 2006
- A convenient plasmid system for construction of helper‐dependent adenoviral vectors and its application for analysis of the breast‐cancer‐specific mammaglobin promoterThe Journal of Gene Medicine, 2006
- Efficient Tet-Dependent Expression of Human Factor IX in Vivo by a New Self-Regulating Lentiviral VectorMolecular Therapy, 2005